Ahrendt Hans-Joachim, Karckt Ulrich, Pichl Tanja, Mueller Thomas, Ernst Uwe
Klinikum Stuttgart, Frauenklinik, Stuttgart, Germany.
Eur J Contracept Reprod Health Care. 2007 Dec;12(4):354-61. doi: 10.1080/13625180701536771.
To evaluate the effects of an oestrogen-free oral contraceptive (Cerazette; 75 mcg/day desogestrel) in women with oestrogen-related symptoms during previous combined oral contraceptive (COC) use (ERS study) and in women with dysmenorrhoea (DYS study).
Two similarly designed prospective, non-comparative multicentre observational studies were carried out in Germany. Altogether, 403 women with oestrogen-related symptoms during previous COC use and 406 women with dysmenorrhoea took Cerazette continuously. Symptom-related assessments were made at baseline and after 3-4 months, along with bleeding pattern and treatment satisfaction.
In the ERS study, the four oestrogen-related symptoms studied resolved or improved in over 70% of women. Nausea improved/resolved most (92% of women), followed by breast tenderness (90%), oestrogen-related headache (84%) and oedema (74%). In the DYS study, dysmenorrhoea resolved or considerably improved in 93% of the study population. Correspondingly, use of analgesics dropped from 70% of women at baseline to 8% at study end. Adverse events were reported by 7-8% of both study populations and were mainly bleeding irregularities. Most women in both studies were satisfied with treatment (approximately 90%) and wished to continue treatment after study completion (approximately 85%).
Cerazette in this study set-up improved oestrogen-related symptoms and dysmenorrhoea in women affected and treatment was well accepted.
评估不含雌激素的口服避孕药(Cerazette;去氧孕烯75微克/天)对既往使用复方口服避孕药(COC)期间出现雌激素相关症状的女性(ERS研究)以及痛经女性(DYS研究)的影响。
在德国开展了两项设计相似的前瞻性、非对照多中心观察性研究。共有403名既往使用COC期间出现雌激素相关症状的女性和406名痛经女性持续服用Cerazette。在基线时以及3 - 4个月后进行了与症状相关的评估,同时评估了出血模式和治疗满意度。
在ERS研究中,所研究的四种雌激素相关症状在超过70%的女性中得到缓解或改善。恶心改善/缓解的比例最高(92%的女性),其次是乳房胀痛(90%)、雌激素相关头痛(84%)和水肿(74%)。在DYS研究中,93%的研究人群痛经得到缓解或显著改善。相应地,使用镇痛药的女性比例从基线时的70%降至研究结束时的8%。两个研究人群中均有7 - 8%的女性报告了不良事件,主要是出血不规律。两项研究中的大多数女性对治疗感到满意(约90%),并希望在研究完成后继续治疗(约85%)。
在本研究中,Cerazette改善了受影响女性的雌激素相关症状和痛经,且治疗的接受度良好。